Efficacy of therapy with sucrosomial® iron in patients with primary iron deficiency

Anemia in pediatric age

L. Cannavò, F. De Luca, G. Zirilli

University of Messina

Introduction: Microcytic anemia is the most common form of anemia of the pediatric age. In industrialized countries 17% of children under 5 years suffer from iron deficiency anemia.

Objective: The primary purpose of this retrospective work was to verify the effectiveness of the therapy with Sucrosomal® Iron in children with primary iron-deficiency anemia.

Population and methods: 25 children (13 M) aged under 16 years old (mean 6.9 + 4.6) with sideropenic microcytic anemia (Hb value less then -2SD and sideremia and/or ferritin value less then -2SD by age) were studied. Criteria of exclusion: presence of iron deficiency anemia secondary to malabsorption, acute and chronic inflammatory diseases or H. Pylori infection. The levels of Hb, MCV, Sideremia and Ferritin were measured before starting Sucrosomial® Iron therapy (T0) and after 30 and 60 days (T1 and T2, respectively). The response to treatment was also compared in both sexes.

Resuts:

1. Hemoglobin, MCV and sideremia values increased significantly to T2 (p = 0.006, 0.005 and p = 0.03, respectively).
2. Ferritin values are increased, although not significantly (T1 p = 0.06, T2 p = 0.48).
3. No significant differences emerged when comparing the therapeutic response in the two sexes (T1 p = 0.43, T2 p = 0.48).

All patients tolerated martial therapy well, with no side effects reported.

Conclusions: Treatment with Sucrosomal® Iron improves the values of Hb, MCV and Sideremia after 60 days. This improvement was statistically significant. The absence of side effects contributes positively to adherence to therapy.